Literature DB >> 16472183

Development of miltefosine for the leishmaniases.

J D Berman1.   

Abstract

The leishmaniases consist of visceral and cutaneous syndromes present in > 30 endemic regions of the world. Miltefosine (hexadecylephosphocholine) is the first oral agent that is effective and tolerated for both visceral and cutaneous disease in several endemic regions, and represents a major advance in the treatment of these diseases.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16472183     DOI： 10.2174/138955706775475993

Source DB:  PubMed          Journal:  Mini Rev Med Chem        ISSN： 1389-5575            Impact factor:   3.862


  4 in total

1.  Trypanothione reductase high-throughput screening campaign identifies novel classes of inhibitors with antiparasitic activity.

Authors:  Georgina A Holloway; William N Charman; Alan H Fairlamb; Reto Brun; Marcel Kaiser; Edmund Kostewicz; Patrizia M Novello; John P Parisot; John Richardson; Ian P Street; Keith G Watson; Jonathan B Baell
Journal:  Antimicrob Agents Chemother       Date:  2009-04-13       Impact factor: 5.191

2.  In vitro bactericidal activity of the antiprotozoal drug miltefosine against Streptococcus pneumoniae and other pathogenic streptococci.

Authors:  Daniel Llull; Luis Rivas; Ernesto García
Journal:  Antimicrob Agents Chemother       Date:  2007-03-12       Impact factor: 5.191

3.  Studies on the antileishmanial mechanism of action of the arylimidamide DB766: azole interactions and role of CYP5122A1.

Authors:  Trupti Pandharkar; Xiaohua Zhu; Radhika Mathur; Jinmai Jiang; Thomas D Schmittgen; Chandrima Shaha; Karl A Werbovetz
Journal:  Antimicrob Agents Chemother       Date:  2014-06-02       Impact factor: 5.191

4.  Bioactivity of miltefosine against aquatic stages of Schistosoma mansoni, Schistosoma haematobium and their snail hosts, supported by scanning electron microscopy.

Authors:  Maha M Eissa; Samia El Bardicy; Menerva Tadros
Journal:  Parasit Vectors       Date:  2011-05-11       Impact factor: 3.876
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.